PBSV (Pharma-Bio Serv) Piotroski F-Score: 7 (As of Aug. 02, 2026) — 40% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PBSV Pharma-Bio Serv Inc PBSV
43 GF Score
Price $0.42
GF Value $0.58
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Pharma-Bio Serv Piotroski F-Score?

Pharma-Bio Serv PBSV -27.16% 43 Piotroski F-Score is 7 as of Aug. 02, 2026, which is 40% above its 10-year median of 5.00. GuruFocus rates PBSV with a GF Score™ of 43/100 and a GF Value™ of $0.58 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 646 Healthcare Providers & Services companies, Pharma-Bio Serv ranks better than 88.54% on this metric.

Good Sign:

Piotroski F-Score is 7, indicates a very healthy situation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Pharma-Bio Serv has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

The historical rank and industry rank for Pharma-Bio Serv's Piotroski F-Score or its related term are showing as below:

PBSV' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 5   Max: 9
Current: 7

During the past 13 years, the highest Piotroski F-Score of Pharma-Bio Serv was 9. The lowest was 2. And the median was 5.

Pharma-Bio Serv  (OTCPK:PBSV) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Pharma-Bio Serv Piotroski F-Score Related Terms


Pharma-Bio Serv Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Pharma-Bio Serv's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharma-Bio Serv Piotroski F-Score Chart

Pharma-Bio Serv Annual Data
Trend Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23 Oct24 Oct25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.00 7.00 8.00 3.00 5.00

Pharma-Bio Serv Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.00 5.00 5.00 5.00 7.00

PBSV vs MGRX, BFRG, VYND: Piotroski F-Score Comparison

For the Health Information Services subindustry, Pharma-Bio Serv's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharma-Bio Serv Piotroski F-Score vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Pharma-Bio Serv's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Pharma-Bio Serv's Piotroski F-Score falls into.


PBSV
43GF Score
Pharma-Bio Serv Inc PBSV
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Apr26) TTM:Last Year (Apr25) TTM:
Net Income was -0.204 + 0 + 0.033 + 0.233 = $0.06 Mil.
Cash Flow from Operations was 0.237 + 0.28 + -0.39 + -0.365 = $-0.24 Mil.
Revenue was 1.963 + 2.15 + 2.295 + 2.703 = $9.11 Mil.
Gross Profit was 0.574 + 0.749 + 0.722 + 0.902 = $2.95 Mil.
Average Total Assets from the begining of this year (Apr25)
to the end of this year (Apr26) was
(13.904 + 13.586 + 13.653 + 13.548 + 11.499) / 5 = $13.238 Mil.
Total Assets at the begining of this year (Apr25) was $13.90 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Total Current Assets was $11.29 Mil.
Total Current Liabilities was $1.05 Mil.
Net Income was -0.309 + 0.016 + 0.009 + 0.095 = $-0.19 Mil.

Revenue was 2.418 + 2.333 + 2.471 + 2.417 = $9.64 Mil.
Gross Profit was 0.635 + 0.727 + 0.768 + 0.819 = $2.95 Mil.
Average Total Assets from the begining of last year (Apr24)
to the end of last year (Apr25) was
(16.925 + 16.319 + 16.292 + 16.077 + 13.904) / 5 = $15.9034 Mil.
Total Assets at the begining of last year (Apr24) was $16.93 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Total Current Assets was $13.42 Mil.
Total Current Liabilities was $1.78 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Pharma-Bio Serv's current Net Income (TTM) was 0.06. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Pharma-Bio Serv's current Cash Flow from Operations (TTM) was -0.24. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Apr25)
=0.062/13.904
=0.00445915

ROA (Last Year)=Net Income/Total Assets (Apr24)
=-0.189/16.925
=-0.01116691

Pharma-Bio Serv's return on assets of this year was 0.00445915. Pharma-Bio Serv's return on assets of last year was -0.01116691. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Pharma-Bio Serv's current Net Income (TTM) was 0.06. Pharma-Bio Serv's current Cash Flow from Operations (TTM) was -0.24. ==> -0.24 <= 0.06 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Apr26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Apr25 to Apr26
=0/13.238
=0

Gearing (Last Year: Apr25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Apr24 to Apr25
=0/15.9034
=0

Pharma-Bio Serv's gearing of this year was 0. Pharma-Bio Serv's gearing of last year was 0. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Apr26)=Total Current Assets/Total Current Liabilities
=11.286/1.045
=10.8

Current Ratio (Last Year: Apr25)=Total Current Assets/Total Current Liabilities
=13.417/1.78
=7.53764045

Pharma-Bio Serv's current ratio of this year was 10.8. Pharma-Bio Serv's current ratio of last year was 7.53764045. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Pharma-Bio Serv's number of shares in issue this year was 22.912. Pharma-Bio Serv's number of shares in issue last year was 22.944. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=2.947/9.111
=0.32345516

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=2.949/9.639
=0.3059446

Pharma-Bio Serv's gross margin of this year was 0.32345516. Pharma-Bio Serv's gross margin of last year was 0.3059446. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Apr25)
=9.111/13.904
=0.65527906

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Apr24)
=9.639/16.925
=0.56951256

Pharma-Bio Serv's asset turnover of this year was 0.65527906. Pharma-Bio Serv's asset turnover of last year was 0.56951256. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+0+1+0+1+1+1+1+1
=7

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Pharma-Bio Serv has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 7 mean?
Pharma-Bio Serv (PBSV) has a Piotroski F-Score of 7 as of Aug. 02, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Pharma-Bio Serv and its competitors. This is 40% above median its historical median of 5.00. Over the past decade, Pharma-Bio Serv's Piotroski F-Score has ranged from 2.00 to 9.00. According to the industry distribution chart, Pharma-Bio Serv ranks #74 out of 646 companies in the Healthcare Providers & Services industry, placing it in the top 11.5%.
Is Pharma-Bio Serv's Piotroski F-Score too high?
Pharma-Bio Serv's current Piotroski F-Score of 7 is 40% above median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 9.00. The Healthcare Providers & Services industry median Piotroski F-Score is 5.00. Pharma-Bio Serv's value of 7 is 40% above this industry median. Based on the distribution chart, Pharma-Bio Serv ranks #74 out of 646 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Pharma-Bio Serv has a GF Score™ of 43/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pharma-Bio Serv's Piotroski F-Score compare to MGRX and BFRG?
According to the Healthcare Providers & Services industry distribution chart, Pharma-Bio Serv ranks #74 out of 646 companies for Piotroski F-Score. This places Pharma-Bio Serv in the top 12% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 5.00. Pharma-Bio Serv's value of 7 is 40% above this benchmark. Historically, Pharma-Bio Serv's own Piotroski F-Score has ranged from 2.00 to 9.00 over the past decade. While the company's 10-year median is 5.00 vs. the industry median of 5.00, Pharma-Bio Serv has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Healthcare Providers & Services company?
The median Piotroski F-Score among Healthcare Providers & Services companies is 5.00, based on 646 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pharma-Bio Serv's current Piotroski F-Score of 7 is 40% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Pharma-Bio Serv and its competitors. For the Healthcare Providers & Services industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharma-Bio Serv's current Piotroski F-Score is 7, which is 40% above median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharma-Bio Serv stock overvalued right now?
Based on GuruFocus' analysis, Pharma-Bio Serv (PBSV) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.58, compared to a current price of $0.42 — trading 27.2% below its estimated fair value. The current Piotroski F-Score is 7, which is 40% above median its 10-year median of 5.00 and 40% above the Healthcare Providers & Services industry median of 5.00. Pharma-Bio Serv's overall GF Score™ is 43/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Pharma-Bio Serv (PBSV), the current Piotroski F-Score is 7 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pharma-Bio Serv (PBSV) Overvalued in 2026?

Based on GuruFocus' analysis, Pharma-Bio Serv stock appears to be undervalued. The current stock price of $0.42 is trading 27.2% below its estimated GF Value™ of $0.58. GuruFocus considers Pharma-Bio Serv to be Modestly Undervalued.

Key valuation signals for PBSV:

  • Piotroski F-Score: 7 (40% above median its 10-year median of 5.00)
  • GF Value™: $0.58 vs. price of $0.42 (27.2% below fair value)
  • GF Score™: 43/100 with 1 warning sign
  • Industry Position: 40% above the Healthcare Providers & Services median (#74 of 646)

No single metric tells the full story. See the PBSV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Pharma-Bio Serv Business Description

Address No. 6 Road 696, Pharma-Bio Serv Building, Dorado, PRI, 00646
Pharma-Bio Serv Inc is a compliance and technology transfer services consulting firm. It also provides microbiological testing services and chemical testing services through its laboratory testing facility in Puerto Rico. It has three reportable segments: Puerto Rico technical compliance consulting which is the key revenue driver; United States technical compliance consulting; and Europe technical compliance consulting. The company offers solutions to the pharmaceutical, chemical, biotechnology, medical devices, cosmetic and food industries, and allied products companies. It generates maximum revenue from Puerto Rico and also has its presence in United States, Europe and Other countries.
43GF Score

Get the complete analysis for PBSV

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.42
Price
$0.58
GF Value